Price
$2.03
Decreased by -1.93%
Dollar Volume
1.07 M
ADR%
8.27
Earnings Report Date (estimate)
Nov 3, 22 (-0.4)
Market Cap.
351.31 M
Shares Float
42.79 M
Shares Outstanding
173.06 M
Beta
1.56
Price / Earnings
-1.10
BPR
17.99
20D Range
1.77 2.15
50D Range
1.60 3.53
200D Range
1.60 3.79
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 3, 22 -0.47
Increased by 0.00%
-0.46
Decreased by -2.17%
Aug 4, 22 -0.46
Increased by +2.13%
-0.42
Decreased by -9.52%
May 5, 22 -0.41
Increased by +22.64%
-0.48
Increased by +14.58%
Mar 10, 22 -0.51
Increased by +38.55%
-0.46
Decreased by -10.87%
Nov 3, 21 -0.47
Increased by +34.72%
-0.51
Increased by +7.84%
Aug 5, 21 -0.47
Increased by +24.19%
-0.50
Increased by +6.00%
May 6, 21 -0.53
Increased by +11.67%
-0.60
Increased by +11.67%
Mar 4, 21 -0.83
Increased by +1.19%
-0.77
Decreased by -7.79%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 2.37 M
Increased by +N/A%
-42.77 M
Decreased by -25.82%
Decreased by -1.81 K%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by -100.00%
-42.06 M
Decreased by -26.79%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by -100.00%
-37.06 M
Decreased by -11.41%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 823.00 K
Increased by +N/A%
-41.67 M
Increased by +2.79%
Decreased by -5.06 K%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by -100.00%
-33.99 M
Increased by +8.91%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 1.51 M
Increased by +414.33%
-33.17 M
Decreased by -3.52%
Decreased by -2.20 K%
Increased by +79.87%
Mar 31, 21 269.00 K
Decreased by -20.41%
-33.27 M
Decreased by -11.36%
Decreased by -12.37 K%
Decreased by -39.92%
Dec 31, 20 0.00
Decreased by -100.00%
-42.86 M
Decreased by -4.68%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.